BeOne Medicines (ONC) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic transformation and global growth

• Entered 15th year, reaching a major inflection point with global scale and innovation focus.

• Achieved $1 billion in Q3 revenue, driven by Brukinsa's leadership in BTK inhibitors and 13 new medicines entering the clinic in 2024.

• Announced plans to rename to BeOne Medicines, change ticker to ONC, and re-domicile from Cayman to Switzerland, pending early 2025 shareholder vote.

• Opened flagship U.S. manufacturing facility in New Jersey, strengthening global infrastructure.

• Built internal clinical development team of 3,600 across 40 countries, enabling faster, lower-cost trials and 77% CRO-free in 2024.

Hematology franchise and product leadership

• Brukinsa became the top BTK inhibitor in the U.S. for new CLL patient starts, with broadest label and approvals in 70+ markets.

• Demonstrated superior efficacy and safety over competitors in head-to-head trials, especially in high-risk CLL populations.

• Highlighted strong data for Brukinsa plus Sonro, with 91% MRD and robust PFS, positioning as future fixed-duration regimen.

• Advanced BTK-CDAC degrader program with over 400 patients enrolled, showing early efficacy and safety in refractory CLL; Phase 3 head-to-head trials against pirtobrutinib planned for 2025.

• Addressed investor concerns about competition and pricing, citing underwhelming data from rivals and confidence in Brukinsa's premium.

R&D pipeline and innovation

• Brought 13 new medicines into the clinic in 2024, with a focus on first-in-class and best-in-class assets.

• Six highlighted programs include CDK4, pan-KRAS, B7-H4 ADC, EGFR CDAC, MTAP/PRMT5, and IRAK4, all with major market potential.

• Achieved 30% faster preclinical-to-clinic transitions and 3x faster dose expansion enrollment than industry benchmarks.

• Pipeline includes 16 degrader programs, 19 ADCs in preclinical, and a focus on bispecific/trispecific modalities.

• Multiple internally developed assets with value inflection points expected in 2025–2026.